Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Depreciation (2016)

Agios Pharmaceuticals' Accumulated Depreciation history spans 5 years, with the latest figure at $13.4 million for Q4 2016.

  • For Q4 2016, Accumulated Depreciation rose 74.48% year-over-year to $13.4 million; the TTM value through Dec 2016 reached $13.4 million, up 74.48%, while the annual FY2016 figure was $13.4 million, 74.48% up from the prior year.
  • Accumulated Depreciation reached $13.4 million in Q4 2016 per AGIO's latest filing, up from $7.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $13.4 million in Q4 2016 to a low of $2.8 million in Q4 2012.
  • Average Accumulated Depreciation over 5 years is $6.7 million, with a median of $5.6 million recorded in 2014.
  • Peak YoY movement for Accumulated Depreciation: soared 32.62% in 2014, then surged 74.48% in 2016.
  • A 5-year view of Accumulated Depreciation shows it stood at $2.8 million in 2012, then soared by 52.34% to $4.2 million in 2013, then skyrocketed by 32.62% to $5.6 million in 2014, then skyrocketed by 37.89% to $7.7 million in 2015, then soared by 74.48% to $13.4 million in 2016.
  • Per Business Quant, the three most recent readings for AGIO's Accumulated Depreciation are $13.4 million (Q4 2016), $7.7 million (Q4 2015), and $5.6 million (Q4 2014).